Subtype-specific alterations of the Wnt signaling pathway in breast cancer: Clinical and prognostic significance
Article first published online: 7 DEC 2011
© 2011 Japanese Cancer Association
Volume 103, Issue 2, pages 210–220, February 2012
How to Cite
Mukherjee, N., Bhattacharya, N., Alam, N., Roy, A., Roychoudhury, S. and Panda, C. K. (2012), Subtype-specific alterations of the Wnt signaling pathway in breast cancer: Clinical and prognostic significance. Cancer Science, 103: 210–220. doi: 10.1111/j.1349-7006.2011.02131.x
- Issue published online: 1 FEB 2012
- Article first published online: 7 DEC 2011
- Accepted manuscript online: 25 OCT 2011 11:21AM EST
- (Received June 19, 2011/Revised October 5, 2011/Accepted October 17, 2011/Accepted manuscript online October 25, 2011)
Fig. S1. Flow chart demonstrating sample utilization for different analysis.
Fig. S2. Expression pattern of estrogen and progesterone receptors in breast cancer of Indian patients.
Fig. S3. Alteration patterns of Wnt/β-catenin antagonists in stage I and II/III and IV and Grade I and I/III breast cancer.
Table S1. Summary of oligonucleotides.
Table S2. Antibodies and conditions used for immunohistochemical analyses.
Table S3. Alteration patterns of Wnt/β-catenin antagonists and β-catenin in breast cancer.
Table S4. Association of deletion between Wnt/β-catenin antagonists in breast cancer samples.
Table S5. Association of promoter methylation between Wnt/β-catenin antagonists in breast cancer.
Table S6. Clinicopathological correlation of the alterations (deletion and methylation) of Wnt/β-catenin antagonists in breast cancer.
Data S1. Additional methods including: sample collection and clinical data; microdissection and DNA extraction; deletion analysis; promoter methylation analysis; expression analysis by immunohistochemistry; and statistical analysis.
|CAS_2131_sm_DataS1.doc||44K||Supporting info item|
|CAS_2131_sm_fS1.jpg||550K||Supporting info item|
|CAS_2131_sm_fS2.jpg||156K||Supporting info item|
|CAS_2131_sm_fS3.tif||7855K||Supporting info item|
|CAS_2131_sm_tS1.doc||53K||Supporting info item|
|CAS_2131_sm_tS2.doc||42K||Supporting info item|
|CAS_2131_sm_tS3.xls||96K||Supporting info item|
|CAS_2131_sm_tS4.doc||93K||Supporting info item|
|CAS_2131_sm_tS5.doc||89K||Supporting info item|
|CAS_2131_sm_tS6.doc||55K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.